Oppenheimer Asset Management’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $246K | Buy |
1,257
+20
| +2% | +$3.89K | ﹤0.01% | 1010 |
|
|
2025
Q4 | $215K | Sell |
1,237
-14
| -1% | -$2.55K | ﹤0.01% | 990 |
|
|
2025
Q3 | $238K | Buy |
1,251
+19
| +2% | +$3.37K | ﹤0.01% | 1052 |
|
|
2025
Q2 | $221K | Sell |
1,232
-890
| -42% | -$155K | ﹤0.01% | 1064 |
|
|
2025
Q1 | $359K | Sell |
2,122
-14
| -0.7% | -$2.3K | ﹤0.01% | 927 |
|
|
2024
Q4 | $322K | Sell |
2,136
-39
| -2% | -$6.07K | ﹤0.01% | 963 |
|
|
2024
Q3 | $338K | Sell |
2,175
-78
| -3% | -$11.6K | ﹤0.01% | 968 |
|
|
2024
Q2 | $308K | Buy |
2,253
+60
| +3% | +$8.22K | ﹤0.01% | 972 |
|
|
2024
Q1 | $292K | Sell |
2,193
-97
| -4% | -$12.6K | ﹤0.01% | 965 |
|
|
2023
Q4 | $316K | Buy |
+2,290
| New | +$301K | ﹤0.01% | 975 |
|
|
2023
Q1 | – | Sell |
-1,741
| Closed | -$272K | – | 1144 |
|
|
2022
Q4 | $272K | Sell |
1,741
-305
| -15% | -$43.8K | ﹤0.01% | 987 |
|
|
2022
Q3 | $251K | Buy |
2,046
+39
| +2% | +$5.14K | ﹤0.01% | 1000 |
|
|
2022
Q2 | $268K | Sell |
2,007
-80
| -4% | -$10.9K | ﹤0.01% | 1009 |
|
|
2022
Q1 | $286K | Sell |
2,087
-776
| -27% | -$108K | ﹤0.01% | 1036 |
|
|
2021
Q4 | $496K | Sell |
2,863
-675
| -19% | -$103K | 0.01% | 963 |
|
|
2021
Q3 | $514K | Sell |
3,538
-379
| -10% | -$55.5K | 0.01% | 928 |
|
|
2021
Q2 | $516K | Buy |
3,917
+91
| +2% | +$11.9K | 0.01% | 944 |
|
|
2021
Q1 | $491K | Sell |
3,826
-27
| -0.7% | -$3.33K | 0.01% | 917 |
|
|
2020
Q4 | $459K | Sell |
3,853
-1,004
| -21% | -$122K | 0.01% | 889 |
|
|
2020
Q3 | $556K | Buy |
4,857
+295
| +6% | +$34.9K | 0.01% | 784 |
|
|
2020
Q2 | $519K | Sell |
4,562
-109
| -2% | -$11.6K | 0.01% | 790 |
|
|
2020
Q1 | $376K | Buy |
4,671
+1,788
| +62% | +$185K | 0.01% | 812 |
|
|
2019
Q4 | $308K | Buy |
2,883
+1
| +0% | +$104 | 0.01% | 957 |
|
|
2019
Q3 | $308K | Buy |
2,882
+11
| +0.4% | +$1.13K | 0.01% | 932 |
|
|
2019
Q2 | $292K | Buy |
2,871
+718
| +33% | +$69K | 0.01% | 961 |
|
|
2019
Q1 | $194K | Buy |
2,153
+1,883
| +697% | +$163K | ﹤0.01% | 1048 |
|
|
2018
Q4 | $23K | Sell |
270
-14,846
| -98% | -$1.39M | ﹤0.01% | 1452 |
|
|
2018
Q3 | $1.63M | Sell |
15,116
-624
| -4% | -$68.4K | 0.04% | 477 |
|
|
2018
Q2 | $1.73M | Buy |
+15,740
| New | +$1.64M | 0.04% | 429 |
|
|
2018
Q1 | – | Sell |
-4,303
| Closed | -$402K | – | 1137 |
|
|
2017
Q4 | $402K | Hold |
4,303
| – | – | 0.01% | 849 |
|
|
2017
Q3 | $402K | Buy |
4,303
+3,786
| +732% | +$402K | 0.01% | 853 |
|
|
2017
Q2 | $58K | Sell |
517
-7,033
| -93% | -$744K | ﹤0.01% | 1309 |
|
|
2017
Q1 | $741K | Buy |
+7,550
| New | +$720K | 0.02% | 678 |
|
Other funds holding DGX
VCM
VPM
EIG
Oppenheimer Asset Management's DGX Position: Q1 2026 in Review
Oppenheimer Asset Management increased its Quest Diagnostics (DGX) stake by 1.6% in Q1 2026, buying an estimated $3.89K and bringing the position to 1,257 shares worth $246K. The position accounts for ﹤0.01% of the portfolio, ranked #1010.
Oppenheimer Asset Management first reported a position in DGX in Q1 2017 and has held it in 33 quarters since. The position peaked at $1.73M in Q2 2018. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.
- Oppenheimer Asset Management held 1,257 shares of Quest Diagnostics worth $246K as of Q1 2026.
- Oppenheimer Asset Management bought 20 Quest Diagnostics shares in Q1 2026, an estimated $3.89K.
- Quest Diagnostics made up ﹤0.01% of Oppenheimer Asset Management's portfolio in Q1 2026, its #1010 holding.
- Oppenheimer Asset Management first reported a position in Quest Diagnostics in Q1 2017 and has held it in 33 quarters since.
- Oppenheimer Asset Management's Quest Diagnostics position peaked at $1.73M in Q2 2018.
- 1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.
Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.